Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation (ADPT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADPT · as of Mar 31, 2025
Ownership Breakdown
228
Institutional Holders
▲ 17 vs Q4
$1.14B
Total Inst. Value
▲ $277.36M vs Q4
160.04M
Shares Outstanding
freeFloat 96.51%
152.91M
13F Shares Held
▲ 9.61M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADPT largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP biological products, (no diagnostic substances) | 29.99M | 20.10% | 20.10% | $222.85B | May 15, 2025 | — held |
RUBRIC CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 13.12M | 8.79% | 8.79% | $97.47B | May 14, 2025 | ▼ 1.48M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 12.23M | 8.20% | 8.20% | $90.87B | May 2, 2025 | ▲ 108.9K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 11.14M | 7.47% | 7.47% | $82.80B | May 9, 2025 | ▲ 428.5K |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 7.73M | 5.18% | 5.18% | $57.45B | May 7, 2025 | ▼ 1.69M |
AMERIPRISE FINANCIAL INC biological products, (no diagnostic substances) | 6.64M | 4.45% | 4.45% | $49.35B | May 14, 2025 | ▲ 5.91M |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 6.09M | 4.08% | 4.08% | $45.22B | Apr 25, 2025 | ▼ 747.4K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 6.09M | 4.08% | 4.08% | $45.16B | May 7, 2025 | ▼ 747.4K |
BRAIDWELL LP biological products, (no diagnostic substances) | 4.80M | 3.22% | 3.22% | $35.69B | May 15, 2025 | NEW |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 3.00M | 2.01% | 2.01% | $22.26B | May 15, 2025 | ▼ 3.30M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
20
Increased
+12.72M shares8
New Positions
first time holders20
Decreased
−10.39M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.33M
+12.72M / −10.39M
Net new holders
+8
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADPT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
22
Buy transactions
49
Sell transactions
0.45
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
PISKEL KYLE Chief Financial Officer | May 18, 2026 | Sale | 3,115 | $13.04 | $40.6K | 256.7K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 27, 2026 | Sale | 19,037 | $14.23 | $270.9K | 377.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 22, 2026 | Sale | 19,060 | $14.13 | $269.3K | 390.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 23, 2026 | Sale | 19,060 | $13.74 | $261.9K | 386.5K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 24, 2026 | Sale | 19,060 | $14.02 | $267.2K | 382.1K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 17, 2026 | Sale | 19,060 | $14.57 | $277.7K | 403.8K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 20, 2026 | Sale | 19,060 | $14.55 | $277.3K | 399.5K | Form 4 ↗ |
RUBINSTEIN JULIE President and COO | Apr 21, 2026 | Sale | 30,941 | $14.66 | $453.6K | 395.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adaptive Biotechnologies Corporation (ADPT) is primarily owned by institutional investors, who hold approximately 95.5% of total shares outstanding. Company insiders own approximately 3.49%, while retail and public investors account for the remaining 0.97%.
The largest institutional shareholder of Adaptive Biotechnologies Corporation is VIKING GLOBAL INVESTORS LP, holding approximately 29.99 million shares — equal to 20.10% of outstanding shares — as of March 31, 2025.
A total of 228 institutional investors currently hold ADPT stock, with a combined institutional value of approximately $1.14 billion as of the most recent 13F filing period.
Frequently asked questions
ADPT ownershipAdaptive Biotechnologies Corporation (ADPT) is primarily owned by institutional investors, who hold approximately 95.5% of shares. The largest shareholder is VIKING GLOBAL INVESTORS LP with a 20.10% stake. Company insiders hold 3.49%. Data sourced from SEC Form 13F as of March 31, 2025.